Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 8Terminated 3Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × talimogene laherparepvec × Clear all
NCT07102394 2026-05-08

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Johns Hopkins University

Phase 1 Recruiting
10 enrolled
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡